Roquefort Therapeutics plc (ROQAF)
OTC PINK OTC PINK Primary Summary
Roquefort Therapeutics sells Lyramid for $10.8mln - ICYMI
Roquefort Therapeutics PLC CEO Ajan Reginald talked with Proactive's Stephen Gunnion about the binding share purchase agreement with Pleiades Pharma for its wholly-owned subsidiary, Lyramid. The $10.8 million deal includes both shares and cash.
Roquefort Therapeutics shares up 19% on deal news
Shares in Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) surged 19% in morning trade following the announcement of a term sheet to sell its subsidiary, Lyramid, to Pleiades Pharma for at least $10 million. The deal includes equity in Pleiades, which focuses on clinical and pre-clinical medicines and could involve upfront cash payments.
Roquefort Therapeutics signs term sheet for sale of Midkine portfolio for at least $10m
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has signed a term sheet to sell its subsidiary, Lyramid, to Pleiades Pharma for at least $10 million. The deal includes equity in Pleiades and may involve upfront cash payments.
Roquefort Therapeutics plc (ROQAF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Roquefort Therapeutics plc ever had a stock split?
Roquefort Therapeutics plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Darrin Matthew Disley O.B.E., Ph.D. CEO | OTC PINK Exchange | GB00BMDQ2T15 ISIN |
| US Country | 7 Employees | - Last Dividend | 27 Mar 2026 Last Split | - IPO Date |
Overview
Roquefort Therapeutics plc is a biotechnology firm focused on the innovation of novel cancer treatments. Incorporated in 2020 and situated in London, the United Kingdom, the company specializes in the discovery and development of therapeutic solutions that target various aspects of cancer biology. Leveraging a deep understanding of oncology and cutting-edge biotechnological methodologies, Roquefort Therapeutics strives to advance the field of cancer treatment through its diverse pre-clinical pipeline.
Products and Services
- Midkine Antibodies: Developed as part of its pre-clinical development pipeline, these antibodies have shown significant efficacy and promising results in toxicology studies. The focus on Midkine, a growth factor implicated in the progression of various cancers, targets its role in tumor growth and metastasis, offering a potential therapeutic option for cancer patients.
- Midkine RNA Therapeutics: Encompassing novel anti-cancer gene editing actions, Roquefort Therapeutics' RNA-based treatment options aim to modulate the expression of Midkine at the genetic level. This approach represents a cutting-edge direction in cancer therapy by altering the disease's pathway at its root cause.
- Midkine mRNA Therapeutics: These therapeutics use messenger RNA (mRNA) to stimulate a novel anti-cancer approach, targeting the synthesis of proteins vital for cancer cell growth and survival. By manipulating mRNA, Roquefort Therapeutics seeks to disrupt the production of key proteins that facilitate cancer progression.
- STAT-6 siRNA Therapeutics: Focused on targeting solid tumors, these small interfering RNA (siRNA) therapeutics aim to silence the STAT-6 gene, which plays a significant role in cancer cell proliferation and survival. The demonstration of significant in vivo efficacy highlights the potential of STAT-6 siRNA in treating various solid tumor indications.
- MK Cell Therapy: This novel cell therapy employs multiple mechanisms, including direct and natural killer (NK)-mediated actions, to target and destroy cancer cells. By harnessing the innate power of the immune system, MK cell therapy represents a promising avenue for the treatment of cancers through immunotherapeutic strategies.
